# Tissue Sodium in Pre-hypertensive Patients

> **NCT02236520** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 71 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Chlorthalidone
- **DIETARY_SUPPLEMENT:** Diet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02236520
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2018-05-01
- **Final completion:** 2018-05-01
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2019-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02236520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02236520, "Tissue Sodium in Pre-hypertensive Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02236520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*